These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 23195020)

  • 1. Drug interaction between tacrolimus and ertapenem in renal transplantation recipients.
    Bora F; Aliosmanoglu I; Kocak H; Dinckan A; Uslu HB; Gunseren F; Suleymanlar G
    Transplant Proc; 2012 Dec; 44(10):3029-32. PubMed ID: 23195020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial.
    Pascual J; del Castillo D; Cabello M; Pallardó L; Grinyó JM; Fernández AM; Brunet M
    Transplantation; 2010 Apr; 89(8):994-1000. PubMed ID: 20335831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of diltiazem on pharmacokinetics of tacrolimus in relation to CYP3A5 genotype status in renal recipients: from retrospective to prospective.
    Li JL; Wang XD; Chen SY; Liu LS; Fu Q; Chen X; Teng LC; Wang CX; Huang M
    Pharmacogenomics J; 2011 Aug; 11(4):300-6. PubMed ID: 20514078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of tacrolimus in adult kidney transplant recipients.
    Staatz CE; Willis C; Taylor PJ; Tett SE
    Clin Pharmacol Ther; 2002 Dec; 72(6):660-9. PubMed ID: 12496747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetic vs. concentration-controlled optimization of tacrolimus dosing in renal allograft recipients.
    Kuypers DR
    Clin Pharmacol Ther; 2010 Nov; 88(5):595-6; author reply 597. PubMed ID: 20664539
    [No Abstract]   [Full Text] [Related]  

  • 6. Reduced C0 concentrations and increased dose requirements in renal allograft recipients converted to the novel once-daily tacrolimus formulation.
    de Jonge H; Kuypers DR; Verbeke K; Vanrenterghem Y
    Transplantation; 2010 Sep; 90(5):523-9. PubMed ID: 20592652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients.
    Quteineh L; Verstuyft C; Furlan V; Durrbach A; Letierce A; Ferlicot S; Taburet AM; Charpentier B; Becquemont L
    Basic Clin Pharmacol Toxicol; 2008 Dec; 103(6):546-52. PubMed ID: 19067682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pretransplantation pharmacokinetic curves of tacrolimus in HIV-infected patients on ritonavir-containing cART: a pilot study.
    van Maarseveen EM; Crommelin HA; Mudrikova T; van den Broek MP; van Zuilen AD
    Transplantation; 2013 Jan; 95(2):397-402. PubMed ID: 23250333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conversion from Prograf to Advagraf among kidney transplant recipients results in sustained decrease in tacrolimus exposure.
    Hougardy JM; Broeders N; Kianda M; Massart A; Madhoun P; Le Moine A; Hoang AD; Mikhalski D; Wissing KM; Abramowicz D
    Transplantation; 2011 Mar; 91(5):566-9. PubMed ID: 21192316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients.
    Jain AK; Venkataramanan R; Shapiro R; Scantlebury VP; Potdar S; Bonham CA; Ragni M; Fung JJ
    Liver Transpl; 2002 Sep; 8(9):841-5. PubMed ID: 12200788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients.
    Thervet E; Anglicheau D; King B; Schlageter MH; Cassinat B; Beaune P; Legendre C; Daly AK
    Transplantation; 2003 Oct; 76(8):1233-5. PubMed ID: 14578760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of clinical and safety outcomes associated with conversion from brand-name to generic tacrolimus in transplant recipients enrolled in an integrated health care system.
    Spence MM; Nguyen LM; Hui RL; Chan J
    Pharmacotherapy; 2012 Nov; 32(11):981-7. PubMed ID: 23074134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.
    Fukudo M; Yano I; Yoshimura A; Masuda S; Uesugi M; Hosohata K; Katsura T; Ogura Y; Oike F; Takada Y; Uemoto S; Inui K
    Pharmacogenet Genomics; 2008 May; 18(5):413-23. PubMed ID: 18408564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Blood concentrations and side effects of tacrolimus in a living renal transplantation].
    Ishikawa M; Abo K; Nanba A; Satoh S; Mikawa Y; Higashi T; Nakamura K; Miyazaki M
    Masui; 2001 Mar; 50(3):246-50. PubMed ID: 11296433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dosing tacrolimus based on CYP3A5 genotype: will it improve clinical outcome?
    van Gelder T; Hesselink DA
    Clin Pharmacol Ther; 2010 Jun; 87(6):640-1. PubMed ID: 20485320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Isavuconazole on the Plasma Concentrations of Tacrolimus among Solid-Organ Transplant Patients.
    Rivosecchi RM; Clancy CJ; Shields RK; Ensor CR; Shullo MA; Falcione BA; Venkataramanan R; Nguyen MH
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28674051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation.
    Zhang X; Liu ZH; Zheng JM; Chen ZH; Tang Z; Chen JS; Li LS
    Clin Transplant; 2005 Oct; 19(5):638-43. PubMed ID: 16146556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation.
    Anglicheau D; Flamant M; Schlageter MH; Martinez F; Cassinat B; Beaune P; Legendre C; Thervet E
    Nephrol Dial Transplant; 2003 Nov; 18(11):2409-14. PubMed ID: 14551375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Once daily tacrolimus formulation: monitoring of plasma levels, graft function, and cardiovascular risk factors.
    Meçule A; Poli L; Nofroni I; Bachetoni A; Tinti F; Umbro I; Barile M; Berloco PB; Mitterhofer AP
    Transplant Proc; 2010 May; 42(4):1317-9. PubMed ID: 20534290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of CYP3A5 genotype on renal allograft recipients treated with tacrolimus.
    Chen JS; Li LS; Cheng DR; Ji SM; Sun QQ; Cheng Z; Wen JQ; Sha GZ; Liu ZH
    Transplant Proc; 2009 Jun; 41(5):1557-61. PubMed ID: 19545678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.